Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Shortage Legislation Gains Momentum With Bipartisan House Bill

Executive Summary

Momentum is increasing for efforts to require manufacturers to give advance warning of a drug shortage with legislation now filed in both houses of Congress.
Advertisement

Related Content

FDA's Drug Shortages Strategy Focuses On Prevention, Not "Empire Building"
Drug Shortages: Can The Blame Game Help Find Solutions?
Rx Shortages Defy Easy Solutions, FDA Notes As It Offers Congress Some Ideas
Drug Shortages Are A Matter Of Time As Bill Sponsors Work To Show Warnings Will Help
What’s In A PDUFA Reauthorization? Maybe These Issues…
PDUFA V: Emerging Sponsor Communication Issue Resolved And Expanded
PDUFA V: Emerging Sponsor Communication Issue Resolved And Expanded
Another Busy Year of Drug Recalls Led to Shortages of Injectables
Imports Of Lethal Injection Drug A Law Enforcement Issue, FDA Says
Drug Shortages Bill In Senate Would Increase Manufacturing Disclosures To FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS053528

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel